The Latest Cardiac and Vascular News
ABBOTT PARK, Ill., Oct. 17, 2018 /PRNewswire/ — For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether someone is having a heart attack. New data, published online in JAMA Cardiology, found a new blood test under development that is done right at the patient’s side in as […]
ABBOTT PARK, Ill., Oct. 15, 2018 /PRNewswire/ — Abbott (NYSE: ABT) announced today that Robert B. Ford has been named president and chief operating officer, effective immediately. Mr. Ford, a 22-year Abbott veteran, was most recently executive vice president of Medical Devices, Abbott’s largest business. In addition to his current responsibilities for Medical Devices, Mr. Ford, 45, […]
SAN DIEGO, Sept. 25, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced one-year results from a real-world, international, multicenter, 941-patient study of the company’s Portico™ transcatheter aortic valve replacement (TAVR) system in patients with symptomatic, severe aortic stenosis – a life-threatening narrowing of the heart’s aortic valve. At one year, implantation with […]
SAN DIEGO, Sept. 23, 2018 /PRNewswire/ — Abbott (NYSE :ABT ) today announced positive clinical study results from a randomized controlled trial comparing treatment with the MitraClip® device to guideline-directed medical therapy in select patients with secondary (or functional) mitral regurgitation, or a leaky heart valve, as a result of advanced heart failure. The landmark […]
ABBOTT PARK, Ill., July 26, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced it has initiated a pivotal clinical study in the U.S. of its Tendyne Transcatheter Mitral Valve Replacement (TMVR) system for the treatment of mitral regurgitation. The trial will evaluate the safety and efficacy of the treatment in patients suffering from mitral […]
ABBOTT PARK, Ill., July 18, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2018. Second-quarter worldwide sales of $7.8 billion increased 17.0 percent on a reported basis and 8.0 percent on an organic* basis. Reported diluted EPS from continuing operations under GAAP was $0.40 in the second quarter. Adjusted diluted EPS […]
ABBOTT PARK, Ill., July 12, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for a next-generation version of its leading MitraClip® heart valve repair device used to repair a leaky mitral valve without open-heart surgery. The transcatheter clip-based therapy, now on a third generation […]
PARIS, May 23, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced favorable outcomes from the first 100 patients treated in a global study of its Tendyne Transcatheter Mitral Valve Replacement (TMVR) system, the first and only mitral replacement valve that is repositionable and fully retrievable to allow for more precise implantation, helping improve […]
ABBOTT PARK, Ill., May 23, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for XIENCE SierraTM, the newest generation of the company’s gold-standard XIENCE everolimus-eluting coronary stent system. XIENCE stents are among the world’s most-used and studied stents and have an exceptional safety […]
PARIS, May 22, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced five-year results from the FAME 2 study, which showed that patients had fewer major adverse cardiac events (MACE) when they received a heart stent guided by Abbott’s fractional flow reserve (FFR) diagnostic tool in combination with medical therapy compared to patients […]
